Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)
Status:
Recruiting
Trial end date:
2023-01-05
Target enrollment:
Participant gender:
Summary
Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), increases natriuresis
alone and synergistically when combined with loop diuretics in patients with AHF without
increasing renin angiotensin- aldosterone activity. Thus, adding SGLT2i to the standard loop
diuretic therapy might confer additional decongestive and natriuretic benefits while avoiding
the adverse electrolyte abnormalities and neurohormonal activation associated with other
diuretic combination. These potential benefits may help with improved clinical outcomes, but
clinical evidence is still lacking.